OncoHost will use SomaLogic's SomaScan platform to develop proteomic tests for OncoHost's Prophet diagnostic system to predict patient response to immunotherapy treatments and develop strategies to overcome treatment resistance, the two firms announced on Monday.

Because of the COVID-19 epidemic, the IVD industry has developed rapidly in the past two years, a large amount of capital and talents have poured in. However, with the normalization of epidemic prevention and control, the IVD industry is also returning to the original normal track.

People in the News at Quest Diagnostics, Molecular Assemblies, Informed DNA, More. Quest Diagnostics has named Sam Samad executive vice president and CFO

ASMS Product Launches: Thermo Fisher, Bruker, Waters, Shimadzu, Newomics

On June 8, Singlera Genomics (Shanghai) Ltd. (hereinafter referred to as “Singlera Genomics”) announced that it had completed a 300 million CNY B+ round of financing.

Thermo Fisher Scientific said on Thursday that the US Food and Drug Administration has cleared its Thermo Scientific EliA RNA Pol III and EliA Rib-P tests for aiding in the diagnosis of systemic sclerosis (SSc) and systemic lupus erythematosus (SLE).

Roche subsidiary Foundation Medicine announced on Thursday that its FoundationOne CDx test has been approved by the US Food and Drug Administration as a companion diagnostic with Roche's Rozlytrek (entrectinib).

Recently, MGI and Singapore biotechnology company MiRXES Pte Ltd. (MiRXES) officially reached a strategic partnership.

LumiraDx said on Wednesday that it has received CE marking for a molecular SARS-CoV-2 test and an assay that tests for both SARS-CoV-2 and influenza virus.

Becton Dickinson and CerTest Biotec will collaborate to develop an RT-PCR-based diagnostic test for monkeypox to run on the BD Max System, they announced on Wednesday.

R-Biopharm said on Tuesday that it has acquired AusDiagnostics, an Australian maker of multiplexing molecular diagnostic assays and reagents.

The US Food and Drug Administration last week granted DxLab Emergency Use Authorization for its molecular DxLab COVID-19 test.

The Construction of Mindray, Biotime and Nanomicro R&D Bases Begins

Recently, Fosun Pharma is planning to incorporate OncoCare, one of the largest private oncology medical centers in Singapore.

By the year 2030, pancreatic cancer is expected to become the second most common cause of cancer deaths for both men and women in the United States, according to recent reports. While considered uncommon, inherited gene mutations can increase a person’s risk of developing pancreatic cancer.